Latest News and Press Releases
Want to stay updated on the latest news?
-
TACTT2 trial did not meet its co-primary efficacy endpoints Top-line results from the Phase 3 TACTT3 trial expected in the fourth quarter of 2016 Second quarter 2016 financial results and...
-
Zug, Switzerland, August 16, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
-
Zug, Switzerland, July 19, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
-
Fast Track designation highlights potential of KeyzilenTM to address unmet medical need Top-line results from Phase 3 TACTT2 trial expected next month Zug, Switzerland, July 18, 2016 - Auris...
-
Auris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12
ZUG, Switzerland, July 8, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
-
Top-line results from TACTT3 trial expected in the fourth quarter Data to complement results from TACTT2 trial that are expected in August Zug, Switzerland, June 28, 2016 - Auris Medical...
-
ZUG, Switzerland, June 17, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
-
ZUG, Switzerland, June 16, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
-
Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
Company introduces KeyzilenTM as brand name for AM-101 KeyzilenTM has potential to be first-ever approved therapy for tinnitus Live webcast of event begins today at 8 am EDT ZUG,...
-
AM-101 has potential to be first-ever approved therapy for tinnitus Top-line results from first of two Phase 3 trials expected in August ZUG, Switzerland, June 7, 2016 - Auris Medical...